retatrutide lilly A Study of (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Demand for Unapproved Weight-Loss Drug

Pharmacotherapy for the Management of Obesity in Older Adults & GLP-1 Receptor Agonists Evidence-based obesity treatment is classified into three main approaches: lifestyle interventions encompassing behavioral modification, diet, and physical activity

You may be a good candidate if you check any of these boxes: You have been diagnosed with Type 2 diabetes You have a body mass index (BMI) of: 30 or higher (obese), or 27 or higher (overweight) with at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia

(Graphic: Business Wire) These outcomes stand in stark contrast to other real-world results of GLP-1 weight loss treatments

Over a mean follow-up of approximately 33 months, semaglutide 2.4 mg reduced MACE by 20% (hazard ratio 0.80)

Q3: What are the main concerns for older adults (60+) considering GLP-1 medications

Metabolic Armor ($47 today, then $19/month)